(Total Views: 431)
Posted On: 03/22/2021 5:17:59 PM
Post# of 154118
JLang wrote:
CD16 was good to go, but they decided to get more specific and split into:
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
my response:
Smart! (vs being in too much of a rush)
CD16 was good to go, but they decided to get more specific and split into:
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
my response:
Smart! (vs being in too much of a rush)
(4)
(0)
